Biohaven Ltd.

NYSE:BHVN

Biotechnology

Healthcare
$12.90 -1.62%

-$0.22 today

Market cap
$1.95B
Beta
3.31
P/E (TTM)
-3.1
EPS (TTM)
-$4.39
52W Low $7.48High $18.57

Volume 2.32M

Average 2.47M

BHVN Depreciation & Amortization

Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.

Biohaven Ltd.NYSE: BHVN

Depreciation & Amortization · Q2 FY2026 · quarter ended Jun 2026

Depreciation & amortization growth accelerates

Q2 FY2026 depreciation & amortization of $4.63M rose 133.8% year over year, ahead of the +22.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 95.5% from the prior quarter. Over 3 fiscal years it compounded at +92.7% a year.

Context

  • Depreciation & amortization increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +133.8% holds above the trailing-twelve-month pace of +22.9%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
$4.63M+95.5% QoQ
Last fiscal yearDec 2025
$9.92M+26.3% YoY
LTMJun 2026
$10.67M+22.9% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+133.8%——
1 year+26.3%——
3-year CAGR+92.7%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the income statement

Latest · FY2025
9.92M USD
Year-over-year change
+26.3%
4-year CAGR
+63.4%

Depreciation & Amortization vs competitors

How BHVN compares with its peers on the latest reported figures

  • Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +22.9% is the 3rd highest of 11, against a peer median of -1.2%.
  • Over three fiscal years its annual growth of +92.7% compares with a peer median of +5.3%.
BHVN Competitors
Depreciation & Amortization for BHVN and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ABCLAbCellera Biologics Inc.LTM Sep 2026$32.16M USD-7.6%-4.5%47.4%
XERSXeris Biopharma Holdings, Inc.LTM Mar 2026$12.61M USD+0.4%-1.4%4.0%
BHVNBiohaven Ltd.LTM Jun 2026$10.67M USD+22.9%+92.7%—
NTLAIntellia Therapeutics, Inc.LTM Mar 2026$9.99M USD-2.7%+28.1%15.1%
CLDXCelldex Therapeutics, Inc.LTM Sep 2026$3.73M USD+10.4%+5.3%3333.9%
IMCRImmunocore Holdings plcLTM Mar 2026$3.14M USD-22.4%-18.0%0.8%
IMNMImmunome, Inc.LTM Sep 2026$2.69M USD-3.0%+67.3%—
SIONSionna Therapeutics, Inc.LTM Mar 2026$1.32M USD+41.9%+74.4%—
VERAVera Therapeutics, Inc.LTM Jun 2026$536K USD+89.4%——
PHVSPharvaris N.V.LTM Sep 2026€483K EUR+19.4%+39.9%—
ZBIOZenas BioPharma, Inc.LTM Mar 2026$39K USD-69.3%-10.5%—
Peer median (excluding BHVN) —-1.2%+5.3%15.1%

Competitors are the stored peer set for BHVN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue00000
Cost of Revenue00004.14M
Gross Profit0000(4.14M)
Gross Margin—————
Research & Development181.49M437.07M373.28M795.87M635.07M
Selling, General & Admin37.41M130.86M62.77M89.24M106.17M
Operating Expenses218.9M567.93M436.05M885.11M741.24M
Depreciation & Amortization1.39M1.39M6.91M7.86M9.92M
EBITDA(211.04M)(568.46M)(402.64M)(837.83M)(727.46M)
EBITDA Margin—————
Operating Income(218.9M)(567.93M)(436.05M)(885.11M)(745.38M)
Operating Margin—————
Interest Income0017.73M21.33M14.59M
Interest Expense00000
Other Income / Expenses6.47M(1.91M)26.5M39.42M8M
Income Before Tax(212.43M)(569.84M)(409.55M)(845.69M)(737.38M)
Pre-Tax Margin—————
Income Tax Expense1.37M438K(1.38M)735K1.44M
Net Income(213.8M)(570.28M)(408.17M)(846.42M)(738.82M)
Net Margin—————
EPS (Basic)(5.97)(12.75)(5.73)(9.28)(6.86)
EPS (Diluted)(5.97)(12.75)(5.73)(9.28)(6.86)
Weighted Avg Shares35.82M44.74M71.2M91.23M107.62M
Weighted Avg Shares (Diluted)35.82M44.74M71.2M91.23M107.62M

Biohaven Ltd.

NYSE:BHVN

Intrinsic Alpha fair value

Locked

Current Price

$12.90

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.